72 related articles for article (PubMed ID: 7468018)
21. Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis.
Kajiwara Y; Yamasaki F; Hama S; Yahara K; Yoshioka H; Sugiyama K; Arita K; Kurisu K
Cancer; 2003 Feb; 97(4):1077-83. PubMed ID: 12569609
[TBL] [Abstract][Full Text] [Related]
22. Correlation of endothelial nitric oxide synthase and vascular endothelial growth factor expression with malignancy in patients with astrocytic tumors.
Erdamar S; Bagci P; Oz B; Dirican A
J BUON; 2006; 11(2):213-6. PubMed ID: 17318973
[TBL] [Abstract][Full Text] [Related]
23. Quantitative evaluation of nucleolar features on cytologic material in brain tumor diagnosis.
Scarpelli M; Montironi R; Magi Galluzzi C; Diamanti L
Clin Neuropathol; 1994; 13(6):323-8. PubMed ID: 7851047
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of Hsp-27 in astrocytic brain tumors: an immunohistochemical study.
Assimakopoulou M; Sotiropoulou-Bonikou G; Maraziotis T; Varakis I
Anticancer Res; 1997; 17(4A):2677-82. PubMed ID: 9252700
[TBL] [Abstract][Full Text] [Related]
25. Upregulation of frizzled 9 in astrocytomas.
Zhang Z; Schittenhelm J; Guo K; Bühring HJ; Trautmann K; Meyermann R; Schluesener HJ
Neuropathol Appl Neurobiol; 2006 Dec; 32(6):615-24. PubMed ID: 17083476
[TBL] [Abstract][Full Text] [Related]
26. Telomerase activity and alterations in telomere length in human brain tumors.
Hiraga S; Ohnishi T; Izumoto S; Miyahara E; Kanemura Y; Matsumura H; Arita N
Cancer Res; 1998 May; 58(10):2117-25. PubMed ID: 9605755
[TBL] [Abstract][Full Text] [Related]
27. A method to estimate cell cycle time and growth fraction using bromodeoxyuridine-flow cytometry data from a single sample.
Eidukevicius R; Characiejus D; Janavicius R; Kazlauskaite N; Pasukoniene V; Mauricas M; Den Otter W
BMC Cancer; 2005 Sep; 5():122. PubMed ID: 16176590
[TBL] [Abstract][Full Text] [Related]
28. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies.
Watanabe K; Sato K; Biernat W; Tachibana O; von Ammon K; Ogata N; Yonekawa Y; Kleihues P; Ohgaki H
Clin Cancer Res; 1997 Apr; 3(4):523-30. PubMed ID: 9815715
[TBL] [Abstract][Full Text] [Related]
29. [Role of adrenomedullin in glioblastomas growth].
Boudouresque F; Berthois Y; Martin PM; Figarella-Branger D; Chinot O; Ouafik L
Bull Cancer; 2005 Apr; 92(4):317-26. PubMed ID: 15888388
[TBL] [Abstract][Full Text] [Related]
30. Diffuse malignant transformation of pleomorphic xanthoastrocytoma 21 years later: a matter of time?
Dickerman RD; Anderson A; Morgan J; Cohen AJ
Acta Neurochir (Wien); 2006 Jan; 148(1):95-7; author reply 97. PubMed ID: 16369862
[No Abstract] [Full Text] [Related]
31. Reduced TSC2 RNA and protein in sporadic astrocytomas and ependymomas.
Wienecke R; Guha A; Maize JC; Heideman RL; DeClue JE; Gutmann DH
Ann Neurol; 1997 Aug; 42(2):230-5. PubMed ID: 9266734
[TBL] [Abstract][Full Text] [Related]
32. Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system.
Bresalier RS; Yan PS; Byrd JC; Lotan R; Raz A
Cancer; 1997 Aug; 80(4):776-87. PubMed ID: 9264362
[TBL] [Abstract][Full Text] [Related]
33. Assessment of protein conformation in human benign and malignant astrocytomas by reflectance Fourier transform infrared microspectroscopy.
Lee LS; Chi CW; Liu HC; Cheng CL; Li MJ; Lin SY
Oncol Res; 1998; 10(1):23-7. PubMed ID: 9613454
[TBL] [Abstract][Full Text] [Related]
34. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression.
Mishima K; Kato Y; Kaneko MK; Nishikawa R; Hirose T; Matsutani M
Acta Neuropathol; 2006 May; 111(5):483-8. PubMed ID: 16596424
[TBL] [Abstract][Full Text] [Related]
35. [Current problems in the diagnosis and treatment of malignant tumors of the brain according to findings in the foreign literature].
Romodanov AP; Rudiak KE
Vopr Neirokhir; 1976; (6):54-7. PubMed ID: 1014532
[No Abstract] [Full Text] [Related]
36. [Several parameters of the kinetics of cellular proliferation in human macroglial tumors].
Kotel'nikov VM; Arkhangel'skiĭ VV; Safronov VA
Vopr Neirokhir; 1976; (1):36-41. PubMed ID: 1258445
[TBL] [Abstract][Full Text] [Related]
37. Review of basic concepts of cell kinetics as applied to brain tumors.
Hoshino T; Wilson CB
J Neurosurg; 1975 Feb; 42(2):123-31. PubMed ID: 1089766
[TBL] [Abstract][Full Text] [Related]
38. Erythropoietin and astrocytomas.
Rutka JT
J Neurosurg; 2007 Feb; 106(2):337; discussion 337. PubMed ID: 17410720
[No Abstract] [Full Text] [Related]
39. ImuVert therapy in the treatment of recurrent malignant astrocytomas: nursing implications.
Cress NB; Owens BM; Hill FH
J Neurosci Nurs; 1991 Feb; 23(1):29-33. PubMed ID: 1826714
[TBL] [Abstract][Full Text] [Related]
40. Cell population kinetics of human solid tumors: a statistical analysis in various histological types.
Sasaki T; Sato Y; Sakka M
Gan; 1980 Aug; 71(4):520-9. PubMed ID: 7429089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
